Telmisartan ( 1 ), a substituted dibenzimidazole derivative, is an antihypertensive drug, essentially used to control blood pressure. An improved, cost-effective, and impurity-free process for telmisartan ( 1 ) suitable for large-scale production is described here by addressing various process development issues. The overall yield obtained from this newly developed process is around 50% (over five steps) compared to the literature reported process (21%, over eight steps).
No takes yet. Share an insight, caveat, or question.
Reddy et al. (2006) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: